A multinational, three-arm, randomized, double-blind, placebo-controlled Phase 2b clinical study of NP-120 (Ifenprodil) for the treatment of refractory chronic cough
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Ifenprodil (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms SILINDA
- Sponsors Algernon Pharmaceuticals; Seyltx
- 16 Jul 2024 According to a Seyltx Inc media release, full results of the study will be presented at the London International Cough Symposium July 18th to 19th, 2024.
- 16 Jul 2024 According to a Seyltx Inc media release, design for this study unveiled by the company and first patient enrollment expected in early 2025. Topline data from SILINDA are expected approximately at the end of 2026.
- 09 Jul 2024 According to a Seyltx Inc media release, today announced the results of a study performed that analyzed real world electronic health record (EHR) data and Based on this data, company will optimize enrollment in its Phase 2b clinical trial and more accurately model the commercial opportunity for a product candidate. The study is expected to have the first patient enrolled in 2025.